SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after reports surfaced of a potential partnership with Novo Nordisk to distribute GLP-1 obesity drugs, signaling an end to their prior legal dispute. This development has ignited fervent community discussion about a massive short squeeze due to the stock's high short interest and its strengthened position in the digital health market.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after forming a partnership with Hims & Hers to distribute its obesity drugs, ending a prior feud and surprising the community. This, alongside reports of rapidly accelerating oral Wegovy prescriptions and an FDA crackdown on compounded GLP-1s, is driving discussion that the stock is oversold despite ongoing competitive dynamics with Eli Lilly.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a sharp rebound, driven by the departure of a controversial FDA official, which the community speculates could pave an easier regulatory path for its Huntington's disease gene therapy and is currently fueling a short squeeze.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as it announces a $300 million restructuring charge, fueling speculation among investors about a potential exit from its struggling Converse brand. The community remains divided, with many concerned about ongoing margin pressures and the slow pace of a turnaround, while others see a long-term buying opportunity despite confusing price action around recent tariff news.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara is trending following the FDA's Day 74 Letter confirming MOLBREEVI's Biologics License Application is under full review with a PDUFA target action date of August 22, 2026, and no advisory committee meeting planned. The community sees this as a positive step towards Molbreevi becoming a first-in-class therapy for autoimmune PAP, fueling optimism around its market potential and future valuation.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals ($DAWN) is trending after agreeing to be acquired by Servier for $21.50 per share in cash, a deal valued at approximately $2.5 billion that offers a significant premium. The community is celebrating substantial gains, with many noting how patience and conviction paid off amidst previous buyout speculation and a recent massive volume spike.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Rithm Capital is actively discussed for its impending S&P SmallCap 600 index inclusion, which analysts anticipate will trigger substantial institutional buying, alongside its consistent earnings beats and strategic evolution into a diversified asset manager. The community is vigorously debating the stock's significant undervaluation and the potential for a future C-Corp conversion or spin-off to unlock considerable shareholder value.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating U.S.-Iran tensions have severely disrupted oil tanker traffic through the Strait of Hormuz, propelling crude prices higher. The community is split between calls for further parabolic gains to $150-$200 due to broken supply chains and warnings of a manipulated "blow-off top" and imminent correction, with broader concerns about inflation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Runway Growth Finance Corp. (RWAY) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Runway Growth Finance Corp. (RWAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Runway Growth Finance (RWAY) Projected to Post Quarterly Earnings on Thursday

Runway Growth Finance (NASDAQ:RWAY) will be releasing its Q4 2025 earnings after the market closes on Thursday, March 12. (View Earnings Report at...

Runway Growth Finance Corp. (NASDAQ:RWAY) Receives Average Rating of "Hold" from Analysts

Shares of Runway Growth Finance Corp. (NASDAQ:RWAY - Get Free Report) have been assigned an average rating of "Hold" from the seven brokerages that are covering the firm, MarketBeat reports. Four...

Runway Growth Finance Corp. Announces Quarterly Dividend of $0.33 (NASDAQ:RWAY)

Runway Growth Finance Corp. (NASDAQ:RWAY) announced a quarterly dividend on Thursday, February 26th. Stockholders of record on Tuesday, March 10th will be given a dividend of 0.33 per share on...

Main Street Capital (MAIN) Q4 Earnings and Revenues Top Estimates

Main Street Capital (MAIN) delivered earnings and revenue surprises of +3.81% and +3.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Runway Growth Finance Stock Options

Investors need to pay close attention to RWAY stock based on the movements in the options market lately.

Blue Owl Technology Finance (OTF) Lags Q4 Earnings and Revenue Estimates

Blue Owl Tech (OTF) delivered earnings and revenue surprises of -7.21% and -1.75%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Runway Growth Finance Corp. (NASDAQ:RWAY) Given Consensus Recommendation of "Hold" by Analysts

Shares of Runway Growth Finance Corp. (NASDAQ:RWAY - Get Free Report) have earned an average rating of "Hold" from the seven research firms that are presently covering the company, Marketbeat Ratings...

Runway Growth Finance (NASDAQ:RWAY) Releases Q4 2025 Earnings Guidance

Runway Growth Finance (NASDAQ:RWAY) updated its fourth quarter 2025 earnings guidance. The company provided EPS guidance of 0.310-0.330 for the period, compared to the consensus estimate of 0.360...

Zacks Industry Outlook Highlights New Mountain Finance and Runway Growth Finance

New Mountain Finance and Runway Growth Finance stand out as SBIC lenders to watch as falling rates reshape margins and financing demand.

Runway Growth Finance Corp. is a closed-end investment company, which engages in the provision of senior secured loans to high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company was founded on August 31, 2015 and is headquartered in Chicago, IL.

Current Price	$7.88
Prev Close	$7.97
Open	$7.95
Dividend Yield	16.33%
50-Day Moving Average	$8.84
Beta	0.66
Avg. Volume	438,397.05
PE Ratio	5.39

52-Week High	$11.37
52-Week Low	$7.61
Market Capitalization	$293.92M
EPS (Annual)	$1.89
Price to Book	0.59
Revenue Per Employee	N/A

RWAY
Runway Growth Finance Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RWAY News

RWAYRunway Growth Finance Corp